Nrx Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
NRx Pharmaceuticals reported a significant increase in net loss for Q3 2025, while advancing multiple drug candidates and expanding its clinical services network.
NASDAQ
NRx Pharmaceuticals reported a significantly wider net loss in Q2 2025 and raised substantial doubt about its ability to continue as a going concern, despite advancing key drug candidates and clinic acquisitions.
NASDAQ
NRx Pharmaceuticals details its Q1 2025 financial results and operational progress, highlighting upcoming NDA submissions and the strategic expansion of its HOPE Therapeutics subsidiary.
NASDAQ
10-Q: NRx Pharmaceuticals Reports Q3 2024 Results, Advances Drug Candidates and Strategic Initiatives
NRx Pharmaceuticals' Q3 2024 report highlights progress in drug development, strategic financing, and a settlement, while acknowledging ongoing financial challenges.
NASDAQ
NRx Pharmaceuticals announced its Q2 2024 financial results, highlighting a net loss of $14.4 million for the first six months of 2024, and secured $16.3 million in debt financing to support drug development.
NASDAQ
NRx Pharmaceuticals reported its Q1 2024 financial results, showcasing advancements in clinical trials, strategic partnerships, and the development of novel therapeutics for central nervous system disorders.